期刊文献+

异环磷酰胺联合方案治疗复发或耐药性妇科恶性肿瘤疗效分析 被引量:1

Clinical Analysis of Recurrent or Drug-resistant Malignant Gynecologic TumorsTreated with Ifosfamide Combined Chemotherapy
下载PDF
导出
摘要 [目的]评价异环磷酰胺(IFO)方案对复发或耐药性妇科恶性肿瘤的疗效和毒性反应。[方法]以IFO为主联合化疗 ,治疗35例以往多药多疗程联合化疗失败或复发的卵巢、宫颈、宫内膜及阴道恶性肿瘤。[结果]完全缓解9例 ,部分缓解11例 ,总有效率为57 1 %(20/35)。主要毒性反应为骨髓抑制、消化道反应和脱发。[结论]IFO联合方案对多药耐药性妇科恶性肿瘤均显示出较好疗效 ,是目前治疗耐药或复发性妇科恶性肿瘤的有效方案。 To evaluate the effect and toxicity of ifosfamide (IFO) combined chemotherapy in recurrent or drug resistant malignant gynecologic cancer.Thirty five patients with recurrent or drug resistant ovarian,cervical and endometrial cancers and vaginal malignant tumor were treated with IFO combined chemotherapy.Among 35 patients,complete response were observed in 9(25 7%) and partial response in 11(31 4%) with an overall response rate of 57 1% .The main toxic effects were myelosuppression,gastrointestinal reaction and alopecia.The cardiac,liver,renal and bladdery toxicities were mild.[Conclusion]IFO combined chemotherapy reveals good effect in treating patients with recurrent or drug resistant gynecologic cancer.It should be considered as an effective agent for gynecologic malignancies.
出处 《肿瘤学杂志》 CAS 2001年第2期84-85,共2页 Journal of Chinese Oncology
关键词 异环磷酰胺 药物疗法 妇科恶性肿瘤 耐药 治疗 ifosfamide drug therapy gynecologic neoplasms drug resistant
  • 相关文献

参考文献4

二级参考文献15

  • 1Anthony D. Elias,Lois J. Ayash,J. Paul Eder,Cathy Wheeler,Joan Deary,Lisa Weissman,Myla Hunt,John Critchlow,Lowell Schnipper,Emil Frei,Karen H. Antman. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study[J] 1991,Journal of Cancer Research and Clinical Oncology(4):S208~S213
  • 2Gregory P. Sutton,John A. Blessing,Guy Photopulos,Michael L. Berman,Howard D. Homesley. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies[J] 1990,Cancer Chemotherapy and Pharmacology(1):S55~S58
  • 3Stella M. Davies,Andrew D. J. Pearson,Alan W. Craft. Toxicity of high-dose ifosfamide in children[J] 1989,Cancer Chemotherapy and Pharmacology(1):S8~S10
  • 4Pax H. B. Willemse,Paul E. Jong,Job B. Elema,Nanno H. Mulder. Severe renal failure following high-dose ifosfamide and mesna[J] 1989,Cancer Chemotherapy and Pharmacology(5):329~330
  • 5C. Focan,J. Boossy,D. Focan-Henrard,M. Reginster,J. J. Claessens. Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer[J] 1989,Cancer Chemotherapy and Pharmacology(3):192~193
  • 6Martin Moncrieff,Anabell Foot. Fanconi syndrome after ifosfamide[J] 1989,Cancer Chemotherapy and Pharmacology(2):121~122
  • 7J. Smeitink,M. Verreussel,C. Schr?der,R. Lippens. Nephrotoxicity associated with ifosfamide[J] 1988,European Journal of Pediatrics(2):164~166
  • 8Maria A. Gieron,Larry S. Barak,Jaime Estrada. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors[J] 1988,Journal of Neuro - Oncology(1):29~30
  • 9T. Cerny,J. M. Margison,N. Thatcher,P. M. Wilkinson. Bioavailability of ifosfamide in patients with bronchial carcinoma[J] 1986,Cancer Chemotherapy and Pharmacology(3):261~264
  • 10N. Brock,J. Pohl. Experimental basis of modern ifosfamide therapy[J] 1986,Journal of Cancer Research and Clinical Oncology(1):S28

共引文献91

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部